| ProductNum | picture | CAS No. | Name and description | Formula | Quick order | 
|---|---|---|---|---|---|
| CLA1688 | 
                         | 
                    2408850-14-4 | 
                         Anti-Human CD3ExBCMA (Elranatamab;PF-06863135) 
  | 
                    — | |
| CLA1678 | 
                         | 
                    2329669-78-3 | 
                         Anti-Human CTLA4xLAG3 Bispecific Antibody ( Bavunalimab; XmAb-22841;cytotoxic T-lymphocyte-associated protein 4, CD152;lymphocyte activating 3, lymphocyte-activation 3, CD223) 95+%  | 
                    — | |
| CLA1666 | 
                         | 
                    2329669-72-7 | 
                         Anti-Human PD-1xCTLA-4 Bispecific Antibody(Vudalimab;XmAb-20717,cytotoxic T-lymphocyte-associated protein 4, CD152;programmed cell death 1, PD1, PD-1, CD279) 95+%  | 
                    — | |
| CLA1634 | 
                         | 
                    2226212-40-2 | 
                         Anti-Human CD3xGPRC5D Bispecific Antibody ( Talquetamab; JNJ-64407564; JNJ-7564) 95+%  | 
                    — | |
| CLA1610 | 
                         | 
                    2413817-97-5 | 
                         Anti-Human CD3xClaudin18.2 Bispecific Antibody ( Gresonitamab; AMG 910; ) 95+%  | 
                    — | |
| CLA1601 | 
                         | 
                    1801338-64-6 | 
                         Anti-Human CD3ExCD20 Bispecific Antibody(Odronextamab) 95+%  | 
                    — | |
| CLA1589 | 
                         | 
                    2134641-34-0 | 
                         Anti-Human CD3ExCD20 (Epcoritamab; GEN3013) 95+%  | 
                    — | |
| CLA1578 | 
                         | 
                    2171511-58-1 | 
                         Anti-Human EGFRxMET Bispecific Antibody(Amivantamab; JNJ-61186372) 95+%  | 
                    — | |
| CLA1553 | 
                         | 
                    2119595-80-9 | 
                         Anti-Human CD3xBCMA Bispecific Antibody(Teclistamab ) 95+%  | 
                    — | |
| CLA1510 | 
                         | 
                    2101242-53-7 | 
                         Anti-Human CD3xCEACAM5 Bispecific Antibody(Cibisatamab) 95+%  | 
                    — | |
| CLA1508 | 
                         | 
                    1607793-29-2 | 
                         Anti-Human VEGFAxANGPT2 (Faricimab; RG7716) 95+%  | 
                    — | |
| CLA1500 | 
                         | 
                    1969309-56-5 | 
                         Anti-Human Her2xHer3 (Zenocutuzumab; MCLA-128; PB4188; R040517) 95+%  | 
                    — | |
| CLA1489 | 
                         | 
                    1905409-39-3 | 
                         Anti-Human CD3xCD20 Bispecific Antibody (Mosunetuzumab; BTCT-4465A; R07030816;CD20-TDB; RG7828; CD20 CD3 bispecific antibody.) 95+%  | 
                    — | |
| CLA1401 | 
                         | 
                    1610943-06-0 | 
                         Anti-Human F9xF10 Bispecific Antibody(Emicizumab;RO 5534262, ACE 910;RG6013,hBS910;coagulation factor 10, coagulation factor X;coagulation factor 9, coagulation factor IX) 95+%  | 
                    — | |
| CLA1389 | 
                         | 
                    1509928-04-4 | 
                         Anti-Human IGF1RxHer3 Bispecific Antibody (Istiratumab; MM 141; MM-005) 95+%  | 
                    — | |
| CLA1082 | 
                         | 
                    853426-35-4 | 
                         Anti-Human CD3xCD19 Bispecific Antibody(Blinatumomab; Blincyto; MT103; MEDI-538; MEDI 538; Anti-human CD3 CD19; Human CD3 CD19 bispecific) 95+%  | 
                    — | |
| CLA1659 | 
                         | 
                    2229047-91-8 | 
                         Anti-Human CD3xCD20 (Synonyms: Glofitamab; RO7082859; CD20-TCB ,RG-6026;CD3e, CD3 epsilon;membrane-spanning 4-domains subfamily A member 1, CD20,MS4A1) 95+%  | 
                    — | |
| CLA1494 | 
                         | 
                    2394841-59-7 | 
                         Anti-Human PD-1xCTLA-4 Bispecific Antibody(Cadonilimab) 95+%  | 
                    — | |